US 12371500
Il-7R-alpha specific antibodies for treating acute lymphoblastic leukemia
granted A61KA61K2039/505A61K31/395
Quick answer
US patent 12371500 (Il-7R-alpha specific antibodies for treating acute lymphoblastic leukemia) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The United States of America, as represented by the Secretary, Department of Health and Human Services
- Grant date
- Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 24
- CPC classes
- A61K, A61K2039/505, A61K31/395, A61K39/3955, A61K39/39558